|
FDA Advisory Committee Shoots Down Cornerstone’s Low-Sodium Drug for Two Indications
The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 8–0 against recommending approval of Cornerstone Therapeutics’ lixivaptan to treat hypervolemic hyponatremia associated with heart failure.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives